Compare DexCom, Inc. (DXCM) vs Advanced Drainage Systems Inc (WMS) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

WMS trades at $152.70, up 1.1% on the day, with a bullish technical signal and strong profitability metrics including a 13.98% net income margin and 24.02% ROE. The company recently beat Q1 2026 EPS estimates and announced a dividend, while cash flow from operations remains healthy at $581.49M for 2025. Revenue has been stable around $2.9B, though net income dipped to $450.17M in 2025 from prior years.

Outlook is mixed: analyst consensus targets $184.43 (21% upside) with 41% buy ratings, but a Zacks Strong Sell rating and projected 2026 earnings decline pose risks. Investment appeal lies in valuation support and operational strength, countered by earnings volatility and competitive pressures in water management solutions.